

Synthetic peptide API manufacturing: A mini review of current perspectives for peptide manufacturing

pp 2914–2918

Jon H. Rasmussen



*Corresponding author

Supplementary data available via ScienceDirect

COVER

Cyclic peptide inhibitor of an intracellular protein-protein interaction. X-ray structure of the trans-form of stapled peptide ATSP-7041 bound to Hdm2 at a resolution of 1.40Å. The peptide sequence was originally described by Y. S. Chang, B. Graves, V. Guerlavais, C. Tovar, K. Packman, K.-H. To, K. A. Olson, K. Kesavan, P. Gangurde, A. Mukherjee, T. Baker, K. Darlak, C. Elkin, Z. Filipovic, F. Z. Qureshi, H. Cai, P. Berry, E. Feyfant, X. E. Shi, J. Horstick, D. A. Annis, A. M. Manning, N. Fotouhi, H. Nash, L. T. Vassilev, Tomi Sawyer, Stapled α -helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy, Proc. Natl. Acad. Sci. U S A 110 (2013) E3445–454.

Available online at www.sciencedirect.com**ScienceDirect**

Indexed/Abstracted in: REAXYS, CANCERLIT, Chemical Abstracts, Chemistry Citation Index, Current Awareness in Biological Sciences/BIOBASE, Current Contents: Life Sciences, EMBASE/Excerpta Medica, MEDLINE, PASCAL, Research Alert, Science Citation Index, SciSearch, TOXFILE. Also covered in the abstract and citation database Scopus®. Full text available on ScienceDirect®




ELSEVIER

ISSN 0968-0896

Optimization of peptide-based polyagonists for treatment of diabetes and obesity

pp 2873–2881


Patrick J. Knerr, Brian Finan, Vasily Gelfanov, Diego Perez-Tilve, Matthias H. Tschöp, Richard D. DiMarchi*



Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action

pp 2882–2887


Michaela Gebauer, Arne Skerra*



Nose-to-brain peptide delivery – The potential of nanotechnology

pp 2888–2905


Eleni Samaridou, Maria José Alonso*



Peroral peptide delivery: Peptidase inhibition as a key concept for commercial drug products

pp 2906–2913


Martin Werle, Florian Föger*



Personalized neoantigen vaccines: A new approach to cancer immunotherapy

pp 2842–2849


Amanda R. Aldous, Jesse Z. Dong*



Advances in macrocyclic peptide-based antibiotics

pp 2850–2858


Anatol Luther*, Christian Bisang, Daniel Obrecht*



Therapeutic peptides for CNS indications: Progress and challenges

pp 2859–2862


Bruce H. Morimoto



Peptide therapeutics for the treatment of gastrointestinal disorders

pp 2863–2872


Angelika Fretzen*



Seek & Destroy, use of targeting peptides for cancer detection and drug delivery

pp 2797–2806


Vadim Le Joncour, Pirjo Laakkonen*



Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges

pp 2807–2815


Tomi K. Sawyer*, Anthony W. Partridge, Hung Yi Kristal Kaan, Yu-Chi Juang, Shuhui Lim, Charles Johannes, Tsz Ying Yuen, Chandra Verma, Srinivasaraghavan Kannan, Pietro Aronica, Yaw Sing Tan, Brad Sherborne, Sookhee Ha, Jerome Hochman, Shiyong Chen, Laura Surdi, Andrea Peier, Berengere Sauvagnat, Peter J. Dandliker, Christopher J. Brown, Simon Ng, Fernando Ferrer, David P. Lane



Peptides for optical medical imaging and steps towards therapy

pp 2816–2826


Matteo Staderini, Alicia Megia-Fernandez, Kevin Dhaliwal, Mark Bradley*



Challenges in the design of insulin and relaxin/insulin-like peptide mimetics

pp 2827–2841


Mohammed Akhter Hossain*, Ross A.D. Bathgate*



Improving oral bioavailability of cyclic peptides by *N*-methylation

pp 2766–2773


Andreas F.B. Räder, Florian Reichart, Michael Weinmüller, Horst Kessler*



Heterocycles: Versatile control elements in bioactive macrocycles

pp 2774–2779


Harjeet S. Soor, Solomon D. Appavoo, Andrei K. Yudin*



An opportunistic route to success: Towards a change of paradigm to fully exploit the potential of cell-penetrating peptides

pp 2780–2787

Estel Collado Camps, Roland Brock*



Teixobactin as a scaffold for unlimited new antimicrobial peptides: SAR study

pp 2788–2796

Shimaa A.H. Abdel Monaim, Yahya E. Jad, Ayman El-Faham, Beatriz G. de la Torre*, Fernando Albericio*

